Better Therapeutics to Participate in Two Upcoming Investor Events

Jan 20, 2022


Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, Chief Executive Officer, is scheduled to participate in two upcoming investor events as follows:

  • A virtual fireside chat hosted by LifeSci Capital on January 26 from 12 – 1 p.m. EST. The management team will discuss the current treatment paradigm for cardiometabolic diseases, Better Therapeutics’ approach for treating behavioral root causes using prescription digital therapeutics (PDT), and its lead candidate BT-001, a PDT for treating uncontrolled type 2 diabetes in adults, currently undergoing a potentially pivotal trial. To register for the call, please email Robert Fromberg (
  • The Cowen 42nd Annual Health Care Conference taking place March 7 – 9 in Boston, MA, including a fireside chat on Monday, March 7th, from 2:10-2:40 pm EST.
  • A replay of both firesides will be available on the Presentations and Events section on the Better Therapeutics investor site ( for approximately 90 days after the event.

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines. For more information visit:


Investor Relations:
Mark Heinen

Cassidy McClain

Source: Better Therapeutics, Inc.